| Literature DB >> 26424569 |
Christopher J A Duncan1, Siti M B Mohamad2, Dan F Young3, Andrew J Skelton4, T Ronan Leahy5, Diane C Munday3, Karina M Butler5, Sofia Morfopoulou6, Julianne R Brown7, Mike Hubank8, Jeff Connell9, Patrick J Gavin5, Cathy McMahon10, Eugene Dempsey11, Niamh E Lynch12, Thomas S Jacques13, Manoj Valappil14, Andrew J Cant15, Judith Breuer16, Karin R Engelhardt17, Richard E Randall3, Sophie Hambleton18.
Abstract
Type I interferon (IFN-α/β) is a fundamental antiviral defense mechanism. Mouse models have been pivotal to understanding the role of IFN-α/β in immunity, although validation of these findings in humans has been limited. We investigated a previously healthy child with fatal encephalitis after inoculation of the live attenuated measles, mumps, and rubella (MMR) vaccine. By targeted resequencing, we identified a homozygous mutation in the high-affinity IFN-α/β receptor (IFNAR2) in the proband, as well as a newborn sibling, that rendered cells unresponsive to IFN-α/β. Reconstitution of the proband's cells with wild-type IFNAR2 restored IFN-α/β responsiveness and control of IFN-attenuated viruses. Despite the severe outcome of systemic live vaccine challenge, the proband had previously shown no evidence of heightened susceptibility to respiratory viral pathogens. The phenotype of IFNAR2 deficiency, together with similar findings in STAT2-deficient patients, supports an essential but narrow role for IFN-α/β in human antiviral immunity.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26424569 PMCID: PMC4926955 DOI: 10.1126/scitranslmed.aac4227
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956